首页|Cardiovascular disease and malignant melanoma

Cardiovascular disease and malignant melanoma

扫码查看
原文链接
  • NSTL
  • Lippincott Williams & Wilkins
In the last decade, systemic therapies such as immune checkpoint inhibitors and BRAF-MEK inhibitors have improved the prognosis of high-risk and advanced melanoma. With improved survival, melanoma survivorship is increasingly important, particularly in patients who have a good prognosis or are diagnosed at a younger age. It is increasingly recognized that cancer and its treatment is associated with increased cardiovascular morbidity and mortality. Indeed, data from observational studies and meta-analyses of randomized controls trials in melanoma show that systemic therapies may be associated with cardiac toxicities, such as myocardial infarction, heart failure, myocarditis and stroke. Our review will discuss cardiovascular disease and risk factors in the context of melanoma and outline the importance of cardiovascular risk modification in this population.

cancer survivorscardiovascular diseasesheart disease risk factorsimmune checkpoint inhibitorsmelanomamyocarditisIMMUNE CHECKPOINT INHIBITORSMETABOLIC SYNDROMEBLOOD-PRESSURERISK-FACTORSCANCER-RISKTHERAPYSMOKINGIMMUNOTHERAPYASSOCIATIONSMETAANALYSIS

Wang, Charlie Yue、Zoungas, Sophia、Voskoboynik, Mark、Mar, Victoria

展开 >

Victorian Melanoma Serv,Alfred Hosp

Sch Publ Hlth & Preventat Med,Monash Univ

Dept Oncol,Alfred Hosp

2022

10.1097/CMR.0000000000000817

Melanoma research

Melanoma research

SCI
ISSN：0960-8931
年,卷(期)：2022.32(3)
  • 3
  • 75